Princess Maria Carolina is 'lucky to be alive' after surviving serious motorcycle accident
Print Close
By Stephanie Nolasco
Published May 30, 2025
Princess Maria Carolina of Bourbon-Two Sicilies is "lucky to be alive" after suffering a motorcycle accident.
The Italian royal took to Instagram on Wednesday and shared multiple photos of herself recovering at the hospital. In the series of photos, she is seen wearing a helmet and then a neck brace. One photo showed her with wires surrounding her head.
In her Instagram post, Maria Carolina warned her 173,000 followers to be careful when out on the road. The eldest daughter of Prince Carlo, Duke of Castro, and Princess Camilla, Duchess of Castro, recently attended the 78th annual Cannes Film Festival on May 13 in France.
PRINCESS ANNE ADMITS HOSPITAL STAFF HAD TO FILL IN 'THE BLANKS' AFTER SUFFERING CONCUSSION, MEMORY LOSS
"I'm incredibly lucky to be alive," the 21-year-old began her post. "I crashed headfirst into a wall whilst riding a motorcycle and ended up in reanimation in the Intensive Care Unit. Surviving this was nothing short of a miracle."
"I wanted to share my own experience as I've realized now more than ever that motorcycles are powerful and thrilling but also unforgiving," she shared. "Please ride with care. Wear full protection, especially a proper helmet. Mine saved my life."
"My deepest thanks to the outstanding team at Centre Hospitalier Princesse Grace for their expert care during those critical days, and to the emergency medical team and first responders on the scene, whose quick and decisive actions in those first moments made all the difference," Maria Carolina concluded her post with a praying emoji.
CLICK HERE TO SIGN UP FOR THE ENTERTAINMENT NEWSLETTER
Fox News Digital reached out to the royal's office for comment.
It is believed that the socialite suffered her accident days after attending the Monaco Grand Prix over Memorial Day weekend, People magazine reported. According to the outlet, she lives between Paris, Monte Carlo and Rome.
Maria Carolina, who also goes by "Carolina," is a member of the Spanish branch of Bourbons, Tatler magazine reported. They ruled Southern Italy and Sicily for over a century. She is described as "one of society's most eligible beauties." Maria Carolina is a sportswoman and made a cameo in 2014's "Grace of Monaco," starring Nicole Kidman as the late Hollywood actress-turned-princess.
LIKE WHAT YOU'RE READING? CLICK HERE FOR MORE ENTERTAINMENT NEWS
According to the royal's website, Maria Carolina is an ambassador of the Passion Sea Project, a nonprofit that advocates the preservation of our waters. She also supports the Ocean 1 project, UNICEF and the Italian Association "Salvamamme." She previously completed an internship at the Monaco Red Cross.
WATCH: ITALIAN PRINCE EXPLAINS DECISION TO RENOUNCE THRONE TO FASHION MODEL DAUGHTER
CLICK HERE TO GET THE FOX NEWS APP
Maria Carolina is also active on TikTok alongside her younger sister, Princess Maria Chiara. She told Tatler in 2022 that she saw the social media platform as a space to share "important messages such as fighting against gender inequality, racism or climate change." Print Close
URL
https://www.foxnews.com/entertainment/princess-maria-carolina-survives-serious-motorcycle-accident-lucky-alive
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Chronotherapy in RA Treatment: Tantalizing but Under-Studied
Morning stiffness is common for people with arthritis and that got researchers to thinking that if they could time drug therapy to match the body's rhythms when pain receptors are most active, they could relieve that morning stiffness and potentially target flares. That concept, known as chronotherapy or chronomedicine, aims to synchronize drug delivery to the body's circadian rhythms. A few small clinical trials and observational studies have evaluated this concept, but most recently researchers in Japan completed a multicenter, nonrandomized, controlled study that found that almost twice as many patients who took baricitinib at night had a measurable improvement in symptoms than patients who took the Janus kinase (JAK) inhibitor in the morning. Amanda Sammut, MD 'Chronotherapy refers to the strategic timing of medication, therapies, or other medical interventions to align with the body's natural circadian rhythms,' Amanda Sammut, MD, chief of rheumatology at Harlem Hospital Center in New York City, told Medscape Medical News. 'The goal of chronotherapy is to optimize therapeutic efficacy and minimize adverse events.' Progress Slows After Nobel Prize In 2017, Jeffrey Hall, Michael Rosbash, and Michael Young won the Nobel Prize in Medicine for their work isolating a gene that controls the normal daily biological rhythms. However, as researchers in Italy who have studied chronotherapy in inflammatory joint diseases have noted, transition of that knowledge to clinical practice has proceeded slowly. 'Growing knowledge of chronobiology applied to inflammatory joint diseases could stimulate the development of new drug strategies to treat patients in accordance with biological rhythms and minimize side effects,' the Italian researchers wrote. 'It should be evidence-based,' John Hogenesch, PhD, a neuroscientist at Cincinnati Children's Hospital, Cincinnati, who has researched circadian rhythms, told Medscape Medical News. 'Yet there are only about 140 studies in 50 years looking at drug timing.' Sammut noted that chronotherapy is not yet incorporated into major rheumatoid arthritis (RA) treatment guidelines. 'The temporal administration of anti-inflammatory agents to coincide with this cytokine surge presents a theoretically sound strategy to improve disease activity,' she said. Akira Hashiramoto, MD, PhD The most recent research in Japan, led by Akira Hashiramoto, MD, PhD, at Kobe University, Kobe, Japan, assigned 122 patients with RA to four open-label treatment groups: Either baricitinib 2 mg or 4 mg in the morning or evening. The primary endpoint was the percentage of patients with at least 20% improvement in the American College of Rheumatology response criteria (ACR20) at 12 weeks. Some of the secondary endpoints included ACR20, ACR50, and ACR70 response rates at other timepoints as well as changes in the Clinical Disease Activity Index (CDAI) at the same timepoints out to 1 year. Hashiramoto told Medscape Medical News that the changes in swollen joint count (SJC) significantly improved in the evening vs the morning dosing group throughout the 52-week study period, and that changes in tender joint count, patient global assessment, and physician global assessment mostly occurred before 3 months. 'Therefore, we believe that the most important mechanism for achieving sustained CDAI remission at weeks 12, 24, and 52 is that chronotherapy maximized the effect of baricitinib by week 12 after initiation, when all components of CDAI have responded well,' he said. 'The results demonstrate the crucial importance of the treat-to-target strategy.' Earlier studies demonstrated the potential of chronotherapy. Researchers in Berlin, led by Frank Buttgereit, MD, at Charité-Universitätsmedizin Berlin, Berlin, Germany, reported in 2008 that modified-release prednisone reduced the duration of morning stiffness in RA. In 2013, Buttgereit's group reported that low-dose prednisone chronotherapy when added to existing disease-modifying antirheumatic drugs produced significantly higher response rates than placebo for ACR20 — 48% vs 29% ( P < .001), and more than double the rate for a 50% improvement (22% vs 10%, P < .006). A 2011 study in Japan found that methotrexate chronotherapy can improve RA symptoms compared with traditional dosing methods, but Sammut cautioned that the results may not be entirely related to chronotherapy. The study switched patients from the standard methotrexate dose three times daily to once daily at bedtime, but with the same weekly dosing. 'So even though the results showed improved disease activity scores and functional capacity, it may not be related to the actual chronotherapy portion alone,' Sammut said. Role of the Circadian Clock The body's circadian clock is central to chronotherapy. A few studies have explored the role of the body's internal clock in RA pathophysiology, including one by Buttgereit's group in Berlin. Buttgereit's group reported in 2015 that circadian disruption altered circulating leukocyte rhythms in patients with RA. Specifically, they found the rhythms of effector CD8 + and CD4+ T cells, and interleukin (IL)–6R+ CD8+ T cells were abolished in patients with RA; and that IL-8R+ monocytes, CD20+ CD27+ memory B cells, and CD20+ human leukocyte antigen –DR+ activated B cells, which were not rhythmic in healthy individuals, had rhythmic circulation in the peripheral blood of patients with RA. Researchers at Nova Southeastern University in Davie, Florida, conducted a literature review in 2023 in which they identified four common clock genes that were dysregulated in patients with RA: Circadian locomotor output cycles kaput; brain and muscle ARNT like-1 ; period ; and cryptochrome. Research has also been conducted on the diurnal variation of symptoms of polymyalgia rheumatica. In a 2016 observational study, Danish researchers reported that plasma concentrations of IL-6, IL-8, tumor necrosis factor–α, IL-1β, and IL-4 varied with time in both patients treated with prednisolone and untreated patients, peaking between 4:00 AM and 8:00 AM. With the exception of IL-1β, concentrations of these cytokines and of IL-10 were higher throughout the 24-hour observation period in treated patients, as were melatonin and cortisol levels, the latter peaking around 2:00 AM and 8:00 AM, respectively. Farshid Guilak, PhD In his laboratory at Shriners Hospitals for Children — St. Louis — Farshid Guilak, PhD, has been researching circadian rhythms and timed-release therapy to minimize arthritic flares and prevent disease progression in people with RA or juvenile idiopathic arthritis. 'It turns out that not only does our brain have this region that cycles but virtually every other tissue in the body is on a 24-hour clock,' Guilak told Medscape Medical News. 'Unlike the master clock, they're called the peripheral clocks.' These peripheral clocks in the joints dictate the ebb and flow of pain within them, he said. 'The exact reason is not completely known, but my belief is that our tissues also have periods of activity and rest,' Guilak said. 'During the night we elevate a lot of the proteins and genes that are related to repair and regeneration, things that are related to cleaning out the cells, such as the process of autophagy. It's very important in the brain and memory that if you don't have these sleep periods, you don't actually allow your tissues to reset and repair themselves.' Inflammatory mediators peak between 3:00 AM and 5:00 AM, he said. 'This is one reason why many people with arthritis wake up with morning stiffness,' he said. 'The clock regulates about 50% of drug transporters, targets, and metabolizing enzymes,' Hogenesch said. 'About half of all small-molecule drugs have a short (less than 12-hour) half-life. This means as many as 25% of all drugs may be influenced by when they are taken.' Guilak's group reported that people who work night shift had a 25% higher risk for knee osteoarthritis and a 30% higher risk of having knee replacement than nonshift workers. 'Disruption of sleep is a major risk factor for arthritis,' he said. 'Doing shift work or getting < 6 hours of sleep a night significantly increases the risk of osteoarthritis.' Challenges in Adapting Chronotherapy in RA Chronotherapy faces several barriers before it gains wider acceptance as a treatment approach in RA. One involves identifying specific circadian patterns in individual patients. 'The gold standard is the dim-light melatonin onset assay, which is only done in a tiny subset of patients in a tiny subset of academic medical centers,' Hogenesch said. More practical methods, he said, are using surveys, such as the Munich ChronoType Questionnaire, or actigraphy, which uses wearables, such as a Fitbit or Oura ring. 'So [it will be] surveys and wearables for the near future,' he said. The complexity of medical regimens for patients with RA poses another barrier to wider acceptance, Summat said. 'The medication regimen for patients with RA, and for many other chronic diseases, usually includes multiple medications,' she said. 'When you include timings of medications, it may make it more complicated and more difficult to adhere to the regimen.' But other patients may be amenable to having a medication schedule, Sammut said. 'Timing of medications is something that we should think about in our patients already,' she said. 'For instance, if a patient is on a proton pump inhibitor, we would recommend taking it on an empty stomach half an hour before eating or drinking anything.' She suggested that physicians and pharmacists should collaborate on developing medication plans for patients. Individual patients' sleep schedules are another factor to consider with chronotherapy, Sammut added. Chronotherapy With Other Drugs The JAK inhibitors tofacitinib and upadacitinib could potentially be used for chronotherapy in RA, Hashiramoto said. 'The half-life, time after administration of the drug to reach maximum plasma concentration, or drug withdrawal of tofacitinib and upadacitinib are different from that of baricitinib, so the efficacy of bedtime dosing must be demonstrated in clinical trials,' he said. 'However, in our limited experience, tofacitinib tends to respond well in patients who start with only a single evening dose, with similar results to baricitinib 2 mg in the evening,' he said. 'For upadacitinib, once daily in the evening is as effective as baricitinib.' Based on his group's research, Hashiramoto said that chronotherapy does not increase adverse events with either tofacitinib or upadacitinib. 'We hope that follow-up studies of chronotherapy will be conducted in Europe and the United States, not only for baricitinib, but also for other JAK inhibitors,' he said. Emerging Research: Unlocking Gene Circuits Guilak's research group has been investigating 'chronogenetics,' circadian-based gene circuits that can be programmed into stem cells and that, once implanted in the body, match the patient's circadian clock to deliver anti-inflammatory drugs daily at a specific time. The stem cells are administered in a drug-eluting implant — 'like a spaghetti string rod full of cells injected under the skin,' he said — that is inserted into the joint. It's designed to release drugs once a day. Guilak reported that these gene circuits produced effective amounts of IL-1 receptor antagonist in mice. More recently, Guilak's group reported on an implant that responds to both circadian and inflammatory signals to release therapeutic levels of IL-1 receptor antagonist not only at a specific time but also in response to activation of pain receptors. His group recently received a grant from the Advanced Research Project Agency for Health to develop the implant. 'Our goal is to get this into patients in the next 3-5 years,' he said. Hashiramoto reported receiving honoraria from AbbVie and honoraria and grants from Eli Lilly Japan. Guilak is an employee and shareholder of Cytex Therapeutics and has applied for patents on concepts on chronogenetics. Sammut and Hogenesch reported no relevant financial relationships.
CNN
an hour ago
- CNN
Pants ‘singed off her body': Eyewitness describes injuries in Boulder attack
Brian H., who did not want to give his last name due to safety concerns, described to CNN the scene at the Boulder attack. He and his family were having lunch nearby when he heard that somebody was throwing fire at people. Brian then ran towards the scene.
Yahoo
2 hours ago
- Yahoo
Simon Yates rides away with improbable prize of Giro d'Italia while rivals lose plot
The Mexican standoff is a much-loved cinematic device, but the stalemate beloved of western movie script writers has rarely, if ever, decided one of cycling's Grand Tours. The 2025 Giro d'Italia was the exception, appositely as the biggest loser was an actual Mexican, Isaac del Toro, with the unassuming Lancastrian Simon Yates the two-wheeled equivalent of the bandit who skips off with the loot, while two other bandits – in this case Richard Carapaz and Del Toro – stare each other down waiting for the other man to blink. Yates's second career Grand Tour win, forged on the Colle delle Finestre on Saturday afternoon in a peerless display of courage and cunning, and sealed 24 hours later in the streets of Rome, will go down in cycling's annals as one of the most improbable heists the sport has witnessed. Advertisement Related: Britain's Simon Yates seals Giro d'Italia in Rome for second grand tour title The endless joy of the Grand Tours – Spain, France, Italy – is that they throw up all kinds of delightful scenarios, but there have been few, if any, where the decisive plot line was a frozen stalemate between the cyclists in first and second places, each waiting for the other to move while a third man skipped away to victory. This was probably the most bizarre act of self-immolation in a Grand Tour since 1989, when Pedro Delgado wrecked his race on day one by getting lost en route to the start of the prologue time trial. To understand how this happened, the first key element is Yates himself. Now 32, his career has been marked by two qualities: patience and sang-froid. His ability to wait for the right moment, and to seize that moment, has been the hallmark of his best wins, going back to his earliest triumphs: his 2011 stage win in the Tour de l'Avenir, his 2013 world title in the points race on the velodrome in Minsk, and his Tour of Britain stage win later that year. When he threw caution to the winds, at the Giro in 2018, it backfired spectacularly at the end of the three weeks, in no less a place than the Colle delle Finestre; when he won the Vuelta a few months later, he had learned the lesson and bided his time. That it has taken so long for him to take a second Grand Tour can be largely summed up in one word: Slovenia. Seven years ago, no one would have predicted the rise and rise of Tadej Pogacar and Primoz Roglic. Yates first looked like a potential winner on the day that Del Toro took the race lead, the gravel‑road stage into Siena, and he had ridden the perfect race since then, never losing enough time to rule him out, never putting his cards on the table. Advertisement It took more than guts and patience; it needed the other pieces of the tactical jigsaw to slot into place. His team, Visma‑Lease-a-Bike, did what they had to do best: sending a satellite rider ahead in the day's main escape in case of need. Most days, the pawns had had limited impact; here, the strongest and most versatile, the Belgian Wout van Aert, was in the perfect position to help Yates to mess with Del Toro's and Carapaz's minds. Neither the Mexican nor the Ecuadorian had a teammate in place alongside Van Aert, an egregious blunder, because if either man had had an equipier to hand at the key moment – at the foot of the descent off the Finestre with 36km remaining when Yates was still just about within reach – it could well have tipped the balance. Related: Giro d'Italia winner Simon Yates hails 'huge moment in my career' Advertisement Unwittingly, Carapaz's EF Education team slotted in another piece at the foot of the Finestre, where the EF domestiques ensured that the peloton would hit the climb at warp speed, paving the way for Carapaz to attack Del Toro. In the event, the Ecuadorian was unable to dislodge the Mexican, but their violent acceleration achieved something more insidious: it burned off Del Toro's teammates, who had defended his lead impeccably for 11 stages. By the time they rejoined Del Toro, Yates was long gone. Once Yates had flown the coop at the foot of the Finestre, it was Del Toro's job, as the race leader, to pursue the Lancastrian, whether or not he had any teammates with him. But he knew that to do so would expose him to a late attack from Carapaz, who had started the day only 43sec behind. And Carapaz was equally aware that if he chased, Del Toro might be the beneficiary. It needed either to seize the initiative, or for one team manager to issue an ultimatum to his rider. Without that, the upshot was the absorbing but unedifying spectacle of the pair freewheeling as Yates forged ahead with Van Aert – unedifying that is, unless you were a Visma team member, a British cycling fan or a connoisseur of the bizarre twists that bike racing unfailingly produces.
